CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Cancer Management Handbook » Chapter 36: Depression, anxiety, and delirium

Cancer Management: A Multidisciplinary Approach, 12th Edition (2009).
Pages: 1  2  3  4  5  
Next
 

Cancer Management Chapter 36: Depression, anxiety, and delirium

By Ilana Braun, MD | March 15, 2010

Although many cancer patients cope well with their disease, psychiatric disorders occur in almost 50% of patients in the setting of malignancy. Untreated psychological and neuropsychiatric disorders can compromise quality of life as well as treatment compliance. Three behavioral syndromes that are often encountered in clinical practice will be discussed here: depression, anxiety, and delirium.

Depression

Sadness exists on a continuum, ranging from an emotion common in daily life to a syndrome of severe physical and psychological symptoms consistent with a defined psychiatric disorder (Major Depressive Disorder). Several studies of cancer inpatients report Major Depression prevalence rates of 25% to 42%.

Signs and symptoms/diagnosis

Patients with depressive syndromes may experience an array of psychological and somatic symptoms.

Psychological symptoms include dysphoria (sadness), anhedonia (pervasive loss of pleasure in activities), feelings of guilt or low self-esteem, and thoughts of death or suicide.

Somatic symptoms include sleep disturbance (ie, sleeping too much or too little), change in appetite, fatigue, diminished concentration, and psychomotor agitation or withdrawal.

Focus of diagnostic evaluation Although the diagnosis of Major Depressive Disorder requires that greater than half of these symptoms (including dysphoria or anhedonia) be present for at least 2 weeks, patients who do not meet these criteria may be in significant distress, and may be described as having an Adjustment Disorder. In medically ill patients, diagnosis is complicated by the fact that somatic symptoms may also arise as a result of disease and treatment. For this reason, when evaluating the depressed cancer patient, special attention should be paid to those psychological symptoms that are less likely to be directly related to somatic disease or treatment.

Etiology

Psychological causesMajor depressive disorder is common in the general population (point prevalence, ~6%) and is a recurrent disease. Patients with a history of mood disorder are at risk for relapse in the face of a cancer diagnosis. In the setting of malignancy, obvious stressors include news of initial diagnosis, treatment failure, or disease progression. Patients may also confront more subtle stressors, including loss of independence, financial woes, diminished body image, family strain, and existential angst.

Disease- and treatment-related causes

Presenting symptom of malignancy Depression may be a presenting symptom of some primary malignancies, most notably pancreatic carcinoma. Primary and metastatic brain tumors can cause frontal lobe disinhibition syndromes or personality changes that mimic depression and other psychiatric disorders.

Drugs Many drugs used in general medical practice are associated with psychiatric syndromes. The most common of these drugs are β-blockers, anti- hypertensives, barbiturates, opioids, and benzodiazepines. Many primary and supportive therapies for cancer are also commonly associated with depression. They include corticosteroids (also possibly associated with mania), cytokines (especially interferon-alfa and interleukin-2), whole-brain radiation therapy, and chemotherapeutic agents, including procarbazine(Drug information on procarbazine) (Matulane). Patients treated with tamoxifen(Drug information on tamoxifen) may complain of depression or “chemo brain.” The latter term usually refers to cognitive slowing. Treatment of tamoxifen-related depression raises particular challenges. Recent evidence suggests that many antidepressants used to treat these symptoms inhibit tamoxifen’s anti-cancer effect through P450 interactions.

Management

Management of depressive syndromes begins with accurate diagnosis. Clinicians should assess for somatic and psychological symptoms of the syndrome and should always ask about suicidal thoughts or intent. In addition to medication, laboratory assessments should be reviewed, as metabolic disarray, anemia, low B12 levels, and thyroid dysfunction can all contribute to the development of depressive symptoms. Once depression is diagnosed, treatment involves antidepressant medication, sleep aids, when possible, removal of exacerbating agents, and psychotherapy.

Pages: 1  2  3  4  5  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





 
Table of Contents

ONLINE EDITION

Cancer Management: A Multidisciplinary Approach

Medical, Surgical, & Radiation Oncology

 

Edited by
Daniel G. Haller, MD
Professor of Medicine Emeritus
Abramson Cancer Center at the University of Pennsylvania
 

Lawrence D. Wagman, MD
Executive Medical Director
The Center for Cancer Prevention and Treatment
St. Joseph Hospital
 

Kevin A. Camphausen, MD
Chief, Radiation Oncologist, National Cancer Institute

William J. Hoskins, MD
Executive Director of Surgical Activities
Memorial Sloan-Kettering Cancer Center
 

And the publishers of the journal ONCOLOGY

* Updated March to May 2013

   

 


  

Cancers of the head and neck region *

Head and Neck Tumors
John Andrew Ridge, Ranee Mehra, Miriam N. Lango, Steven Feigenberg

Thyroid and Parathyroid Cancers
Ramona Dadu, Peter Ahn, F. Christopher Holsinger, Mimi I. Hu

 

LUNG CANCER *

Non-Small-Cell Lung Cancer
Benjamin Movsas, Julie R. Brahmer, Patrick M. Forde, Kemp H. Kernstine

Small-Cell Lung Cancer, Mesothelioma, and Thymoma
Benjamin Movsas, Walter Scott, Robert A. Chapman

 

Breast cancer *

Breast Cancer Overview
Risk factors, screening, genetic testing, and prevention
Lori Jardines, Sharad Goyal, Paul Fisher, Jeffrey Weitzel, Melanie Royce, Shari B. Goldfarb

Stages 0 and I Breast Cancer
Lori Jardines, Sharad Goyal, Melanie Royce, Shari B. Goldfarb

Stage II Breast Cancer
Lori Jardines, Sharad Goyal, Melanie Royce, Shari B. Goldfarb

Stages III and IV Breast Cancer
Lori Jardines, Sharad Goyal, Melanie Royce, Ishmael Jaiyesimi, Shari B. Goldfarb

 

GASTROINTESTINAL CANCERS *

Esophageal Cancer
Jimmy J. Hwang, Rajesh V. Iyer, Michael Mulligan

Gastric Cancer
Charles D. Blanke, Deborah Citrin, Roderich E. Schwarz

Pancreatic, Neuroendocrine GI, and Adrenal Cancers
Al B. Benson III, Robert J. Myerson, Aaron R. Sasson

Liver, Gallbladder, and Biliary Tract Cancers
Lawrence D. Wagman, John M. Robertson, Laura Raftery, Bert O'Neil, Keeran R. Sampat

Colon, Rectal, and Anal Cancers
Steven R. Alberts, Deborah Citrin, Miguel Rodriguez-Bigas

Color Atlas: Colorectal Lesions

 

GENITOURINARY MALIGNANCIES *

Prostate Cancer
Judd W. Moul, Andrew J. Armstrong, Joseph Lattanzi

Testicular Cancer
Nasser H. Hanna, Patrick J. Loehrer, Atreya Dash, Mark K. Buyyounouski, Douglas Skarecky

Urothelial and Kidney Cancers
Mark Hurwitz, Philippe E. Spiess, Jorge A. Garcia, Louis L. Pisters

 

GYNECOLOGIC MALIGNANCIES *

Cervical Cancer
Leda Gattoc, Carlos A. Perez, William Tew, Sharmila Makhija

Uterine Corpus Tumors
Kathryn M. Greven, Maurie Markman, David Scott Miller

Ovarian Cancer
Stephen C. Rubin, Paul Sabbatini, Akila N. Viswanathan

 

SKIN CANCERS *

Melanoma and Other Skin Cancers
Mary S. Brady, Aradhana Kaushal, Christine Ko, Richard D. Carvajal

Color Atlas: The ABCDEs of Moles and Melanomas

Color Atlas: Skin Lesions

 

Sarcomas *

Bone Sarcomas
Warren Chow, Karl Haglund, R. Lor Randall

Soft-Tissue Sarcomas
Peter W. T. Pisters, Mitchell Weiss, Robert Maki

 

Brain TUMORS *

Primary and Metastatic Brain Tumors
Jay S. Loeffler, John de Groot, Nicole Shonka, Daniel P. Cahill

 

other SOLID TUMORS *

AIDS-Related Malignancies
Ronald T. Mitsuyasu, Deepa Reddy, Jay S. Cooper

Carcinoma of an Unknown Primary Site
John D. Hainsworth, Lawrence M. Weiss

 

hematologic malignancies

Hodgkin Lymphoma
Joachim Yahalom, David Straus, Dennis Eichenauer, Volker Diehl

Non-Hodgkin Lymphoma
Andrew M. Evens, Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen

Multiple Myeloma and Other Plasma Cell Dyscrasias
Sundar Jagannath, Paul Richardson, Nikhil C. Munshi

Acute Leukemias
Margaret R. O'Donnell

Chronic Myeloid Leukemia
Jorge E. Cortes, Richard T. Silver, Hagop Kantarjian

Chronic Lymphocytic Leukemia
Nicole Lamanna, Mark A. Weiss, Kieron Dunleavy

Myelodysplastic Syndromes
Guillermo Garcia-Manero, Alan List, Hagop Kantarjian, Jorge E. Cortes

Hematopoietic Cell Transplantation
Stephen J. Forman, Ryotaro Nakamura

 

Palliative and SUPPORTIVE CARE *

Pain Management
Sharon M. Weinstein, Nora Janjan

Management of Nausea and Vomiting
Steven M. Grunberg, Nathan B. Adams, Richard Gralla

Fatigue and Dyspnea
Sriram Yennurajalingam, Eduardo Bruera

Anorexia and Cachexia
Aminah Jatoi

Long-Term Central Venous Access
Stephen P. Povoski

 

COMPLICATIONS

Oncologic Emergencies and Paraneoplastic Syndromes
Carmen P. Escalante, Ellen Manzullo, Mitchell Weiss

Infectious Complications
Sanjeet Dadwal, Jane Kriengkauykiat, James Ito

Fluid Complications
Frederic W. Grannis, Jr., Lily Lai

Color Atlas: Dermatologic Adverse Events Associated With Targeted Therapies

 

APPENDICES

Response Evaluation Criteria and Performance Scales

Cancer Information on the Internet
J. Sybil Biermann

Selected Cancer Drugs and Indications

Selected Chemotherapeutic Agents

Emiliano Calvo, MD, PhD and Antonio Calles, MD

 


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
Most Popular
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Depression, Anxiety, And Delirium
Evidence on Depression, Anxiety, And Delirium
Guidelines on Depression, Anxiety, And Delirium
Patient Education on Depression, Anxiety, And Delirium
Clinical Trials on Depression, Anxiety, And Delirium
Practical Articles on Depression, Anxiety, And Delirium
Research and Reviews on Depression, Anxiety, And Delirium
All "Depression, Anxiety, And Delirium" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy